Home/ Stocks/ GNPX

Genprex, Inc. Common Stock

GNPX XNAS

$1.89 +0.00 (+0.00%) ▲ 15-min delayed

Open

$1.89

High

$1.92

Low

$1.85

Volume

177.0K

Market Cap

$4.34M

About Genprex, Inc. Common Stock

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 13 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-3,799,240	$-5.00
Q2 2025	$0	$-4,674,901	$-0.17
Q1 2025	$0	$-3,964,601	$-0.26
FY 2024	$0	$-21,111,163	$-5.34

Related Market News

No specific coverage for GNPX yet. Check out our latest market news or earnings calendar.

Get GNPX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Genprex, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.